Update
$Sagimet Biosciences (SGMT.US)$ Reuters· 3 mins agoSagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more